Remoué Annabelle, Conan-Charlet Virginie, Bourhis Amélie, Flahec Glen Le, Lambros Laetitia, Marcorelles Pascale, Uguen Arnaud
Department of Pathology, Brest University Hospital, Brest, F-29220, France.
Inserm U1053 Bordeaux Research in Translational Oncology BaRITOn, Bordeaux, F-33076, France.
Pathol Int. 2019 Feb;69(2):94-96. doi: 10.1111/pin.12766. Epub 2019 Feb 1.
Anti-TRK targeted therapies offer opportunities to treat patients with advanced NTRK1/2/3-rearranged cancers. Beyond NTRK-rearranged secretory breast carcinomas, little is known about NTRK rearrangements and the expression of TRK proteins in non-secretory breast carcinomas. We search for TRK proteins expressions using pan-TRK immunohistochemistry and NTRK1, NTRK2 and NTRK3 rearrangements using fluorescent in situ hybridization (FISH) tests in a set of tissue microarray included breast carcinomas. Only 1/339 invasive breast carcinomas, the only example of secretory subtype, was positive using pan-TRK immunohistochemistry and harboured a NTRK-rearrangement (NTRK1 positive FISH test). According to our results, druggable NTRK rearrangements and related-TRK proteins expression are not encountered in non-secretory breast carcinomas.
抗TRK靶向疗法为治疗晚期NTRK1/2/3重排癌症患者提供了机会。除了NTRK重排的分泌性乳腺癌外，关于非分泌性乳腺癌中NTRK重排及TRK蛋白表达的情况知之甚少。我们在一组包含乳腺癌的组织微阵列中，使用泛TRK免疫组织化学检测TRK蛋白表达，并使用荧光原位杂交（FISH）检测NTRK1、NTRK2和NTRK3重排。在339例浸润性乳腺癌中，只有1例分泌性亚型的病例通过泛TRK免疫组织化学检测呈阳性，且存在NTRK重排（FISH检测NTRK1阳性）。根据我们的结果，在非分泌性乳腺癌中未发现可靶向治疗的NTRK重排及相关TRK蛋白表达。
